2 weeks Ago By Defense World Staff
NewAmsterdam Pharma ( NASDAQ:NAMS – Get Free Report ) CAO Louise Frederika Kooij sold 45,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $15.72, for a total transaction of $707,400.
00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website . NewAmsterdam Pharma Stock Performance Shares of NewAmsterdam Pharma stock traded up $0.
69 during trading on Tuesday, reaching $17.29. The company had a trading volume of 454,562 shares, compared to its average volume of 258,218.
The firm’s fifty day moving average is $16.54 and its 200-day moving average is $18.96.
NewAmsterdam Pharma has a fifty-two week low of $5.63 and a fifty-two week high of $26.35.
NewAmsterdam Pharma ( NASDAQ:NAMS – Get Free Report ) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.
59) by $0.08. The firm had revenue of $2.
28 million for the quarter, compared to the consensus estimate of $2.20 million. Equities analysts forecast that NewAmsterdam Pharma will post -2.
06 earnings per share for the current fiscal year. Wall Street Analysts Forecast Growth View Our Latest Stock Report on NAMS Institutional Investors Weigh In On NewAmsterdam Pharma Institutional investors have recently bought and sold shares of the business. Millennium Management LLC grew its position in NewAmsterdam Pharma by 23.
0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock worth $22,388,000 after acquiring an additional 217,902 shares in the last quarter. Jennison Associates LLC acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at about $22,015,000.
Deerfield Management Company L.P. Series C raised its stake in shares of NewAmsterdam Pharma by 30.
3% in the 2nd quarter. Deerfield Management Company L.P.
Series C now owns 869,250 shares of the company’s stock valued at $16,698,000 after acquiring an additional 202,250 shares in the last quarter. Artal Group S.A.
acquired a new position in NewAmsterdam Pharma during the first quarter valued at approximately $18,920,000. Finally, Janus Henderson Group PLC acquired a new position in NewAmsterdam Pharma in the 1st quarter valued at $15,018,000. 89.
89% of the stock is currently owned by institutional investors and hedge funds. NewAmsterdam Pharma Company Profile ( Get Free Report ) NewAmsterdam Pharma Company N.V.
, a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. Recommended Stories Five stocks we like better than NewAmsterdam Pharma Russell 2000 Index, How Investors Use it For Profitable Trading Why Lennar Stock Could Be the Best Play in the Housing Market How to Find Undervalued Stocks 2 Energy Stocks Fueling the AI Datacenter Boom 3 Home Improvement Stocks that Can Upgrade Your Portfolio Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech? Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.
com's FREE daily email newsletter ..
